SA06270303B1 - شكل بلوري معدل جديد من اللوبينافير - Google Patents
شكل بلوري معدل جديد من اللوبينافير Download PDFInfo
- Publication number
- SA06270303B1 SA06270303B1 SA06270303A SA06270303A SA06270303B1 SA 06270303 B1 SA06270303 B1 SA 06270303B1 SA 06270303 A SA06270303 A SA 06270303A SA 06270303 A SA06270303 A SA 06270303A SA 06270303 B1 SA06270303 B1 SA 06270303B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- lopinavir
- amino
- peak
- infrared spectrum
- solid state
- Prior art date
Links
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 title abstract description 445
- 229960004525 lopinavir Drugs 0.000 title abstract description 424
- 230000004048 modification Effects 0.000 title description 2
- 238000012986 modification Methods 0.000 title description 2
- 239000007787 solid Substances 0.000 claims description 112
- 238000002329 infrared spectrum Methods 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 19
- -1 dimethylphenoxyacetyl Chemical group 0.000 claims description 14
- 238000001228 spectrum Methods 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000004098 Tetracycline Substances 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229940035637 spectrum-4 Drugs 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 188
- 239000013078 crystal Substances 0.000 description 134
- 235000019439 ethyl acetate Nutrition 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 42
- 239000002609 medium Substances 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- 230000009466 transformation Effects 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 239000000843 powder Substances 0.000 description 22
- 238000002441 X-ray diffraction Methods 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000005642 Oleic acid Substances 0.000 description 11
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 229960000311 ritonavir Drugs 0.000 description 11
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 10
- 238000000634 powder X-ray diffraction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000007614 solvation Methods 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 238000012937 correction Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000010287 polarization Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940095564 anhydrous calcium sulfate Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- NPSUUQFUCRTPBZ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O.CCOC(C)=O NPSUUQFUCRTPBZ-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012526 feed medium Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 235000021190 leftovers Nutrition 0.000 description 2
- 238000004476 mid-IR spectroscopy Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FIDGQQIVMWAIAD-UHFFFAOYSA-N 2,2,4,4-tetramethyloxolane Chemical compound CC1(C)COC(C)(C)C1 FIDGQQIVMWAIAD-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- XKIRHOWVQWCYBT-UHFFFAOYSA-N 3-ethylpentan-3-ol Chemical compound CCC(O)(CC)CC XKIRHOWVQWCYBT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- LTEQMZWBSYACLV-UHFFFAOYSA-N Hexylbenzene Chemical compound CCCCCCC1=CC=CC=C1 LTEQMZWBSYACLV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- JANZEZRIRDAFAC-UHFFFAOYSA-N O1CCCC1.CC(=O)C.CC(=O)C Chemical compound O1CCCC1.CC(=O)C.CC(=O)C JANZEZRIRDAFAC-UHFFFAOYSA-N 0.000 description 1
- 240000004072 Panicum sumatrense Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100027997 Schizosaccharomyces pombe (strain 972 / ATCC 24843) omh1 gene Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241001275831 Tanais Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 229910001632 barium fluoride Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QNCMDFVHPFYZNK-UHFFFAOYSA-N butan-1-ol;2-methylpropan-1-ol Chemical compound CCCCO.CC(C)CO QNCMDFVHPFYZNK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- QXAUTEVYLRTVDR-UHFFFAOYSA-N chloroform dichloromethane Chemical compound C(Cl)(Cl)Cl.C(Cl)Cl.C(Cl)(Cl)Cl QXAUTEVYLRTVDR-UHFFFAOYSA-N 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- DJQJFMSHHYAZJD-UHFFFAOYSA-N lidofenin Chemical compound CC1=CC=CC(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O DJQJFMSHHYAZJD-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N p-dimethylbenzene Natural products CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- LOFXCXMHDNGNRQ-UHFFFAOYSA-N prop-1-ynoxybenzene Chemical group CC#COC1=CC=CC=C1 LOFXCXMHDNGNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53825700A | 2000-03-30 | 2000-03-30 | |
| US09/793,536 US6608198B2 (en) | 2000-03-30 | 2001-02-27 | Crystalline pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA06270303B1 true SA06270303B1 (ar) | 2009-08-02 |
Family
ID=27065762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA06270303A SA06270303B1 (ar) | 2000-03-30 | 2001-08-07 | شكل بلوري معدل جديد من اللوبينافير |
| SA01220270A SA01220270B1 (ar) | 2000-03-30 | 2001-08-07 | عقار صيدلي بلوري crystalline pharmaceutical |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA01220270A SA01220270B1 (ar) | 2000-03-30 | 2001-08-07 | عقار صيدلي بلوري crystalline pharmaceutical |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1268442A2 (no) |
| JP (1) | JP2003529592A (no) |
| KR (1) | KR100773258B1 (no) |
| CN (2) | CN1330639C (no) |
| AR (2) | AR033360A1 (no) |
| AU (3) | AU5092001A (no) |
| BG (1) | BG107165A (no) |
| BR (1) | BR0109433A (no) |
| CA (1) | CA2403635A1 (no) |
| CZ (1) | CZ20023529A3 (no) |
| HU (1) | HUP0302675A3 (no) |
| IL (1) | IL151551A0 (no) |
| MX (1) | MXPA02009559A (no) |
| MY (1) | MY128296A (no) |
| NO (1) | NO325005B1 (no) |
| NZ (1) | NZ521183A (no) |
| PE (1) | PE20011232A1 (no) |
| PL (1) | PL359727A1 (no) |
| SA (2) | SA06270303B1 (no) |
| SK (1) | SK14832002A3 (no) |
| TW (1) | TWI284640B (no) |
| WO (1) | WO2001074787A2 (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| ES2459301T3 (es) * | 2009-02-06 | 2014-05-08 | Hetero Research Foundation | Nuevos polimorfos de lopinavir |
| US8637449B2 (en) * | 2009-08-27 | 2014-01-28 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis C virus |
| CN112830899A (zh) * | 2021-01-18 | 2021-05-25 | 合肥华方医药科技有限公司 | 一种洛匹那韦新晶型及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO1998057648A1 (en) * | 1997-06-16 | 1998-12-23 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
-
2001
- 2001-03-07 MY MYPI20011034A patent/MY128296A/en unknown
- 2001-03-21 IL IL15155101A patent/IL151551A0/xx unknown
- 2001-03-21 SK SK1483-2002A patent/SK14832002A3/sk not_active Application Discontinuation
- 2001-03-21 EP EP01924250A patent/EP1268442A2/en not_active Withdrawn
- 2001-03-21 HU HU0302675A patent/HUP0302675A3/hu unknown
- 2001-03-21 AU AU5092001A patent/AU5092001A/xx active Pending
- 2001-03-21 WO PCT/US2001/009112 patent/WO2001074787A2/en active IP Right Grant
- 2001-03-21 BR BR0109433-5A patent/BR0109433A/pt not_active Application Discontinuation
- 2001-03-21 CN CNB018076882A patent/CN1330639C/zh not_active Expired - Lifetime
- 2001-03-21 NZ NZ521183A patent/NZ521183A/en not_active IP Right Cessation
- 2001-03-21 KR KR1020027012849A patent/KR100773258B1/ko active IP Right Grant
- 2001-03-21 CA CA002403635A patent/CA2403635A1/en not_active Abandoned
- 2001-03-21 CZ CZ20023529A patent/CZ20023529A3/cs unknown
- 2001-03-21 AU AU2001250920A patent/AU2001250920B2/en not_active Revoked
- 2001-03-21 JP JP2001572482A patent/JP2003529592A/ja active Pending
- 2001-03-21 MX MXPA02009559A patent/MXPA02009559A/es active IP Right Grant
- 2001-03-21 CN CNA2007101123988A patent/CN101066952A/zh active Pending
- 2001-03-21 PL PL35972701A patent/PL359727A1/xx not_active Application Discontinuation
- 2001-03-29 AR ARP010101522A patent/AR033360A1/es not_active Application Discontinuation
- 2001-03-30 PE PE2001000299A patent/PE20011232A1/es not_active Application Discontinuation
- 2001-05-02 TW TW090107717A patent/TWI284640B/zh active
- 2001-08-07 SA SA06270303A patent/SA06270303B1/ar unknown
- 2001-08-07 SA SA01220270A patent/SA01220270B1/ar unknown
-
2002
- 2002-09-30 NO NO20024679A patent/NO325005B1/no not_active Application Discontinuation
- 2002-10-03 BG BG107165A patent/BG107165A/bg unknown
-
2005
- 2005-06-29 AR ARP050102702A patent/AR049560A2/es unknown
-
2006
- 2006-09-27 AU AU2006222711A patent/AU2006222711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR049560A2 (es) | 2006-08-16 |
| CN101066952A (zh) | 2007-11-07 |
| CZ20023529A3 (cs) | 2003-02-12 |
| BR0109433A (pt) | 2004-08-10 |
| NO20024679L (no) | 2002-09-30 |
| SA01220270B1 (ar) | 2006-11-14 |
| HUP0302675A3 (en) | 2004-03-29 |
| TWI284640B (en) | 2007-08-01 |
| NZ521183A (en) | 2004-03-26 |
| WO2001074787A2 (en) | 2001-10-11 |
| CA2403635A1 (en) | 2001-10-11 |
| PE20011232A1 (es) | 2001-12-08 |
| MY128296A (en) | 2007-01-31 |
| AU2006222711A1 (en) | 2006-10-19 |
| NO325005B1 (no) | 2008-01-14 |
| WO2001074787A3 (en) | 2002-02-07 |
| JP2003529592A (ja) | 2003-10-07 |
| IL151551A0 (en) | 2003-04-10 |
| MXPA02009559A (es) | 2003-05-21 |
| CN1422259A (zh) | 2003-06-04 |
| CN1330639C (zh) | 2007-08-08 |
| AU2001250920B2 (en) | 2006-06-29 |
| KR20030011807A (ko) | 2003-02-11 |
| EP1268442A2 (en) | 2003-01-02 |
| NO20024679D0 (no) | 2002-09-30 |
| PL359727A1 (en) | 2004-09-06 |
| KR100773258B1 (ko) | 2007-11-05 |
| BG107165A (bg) | 2003-07-31 |
| AU5092001A (en) | 2001-10-15 |
| SK14832002A3 (sk) | 2003-02-04 |
| AR033360A1 (es) | 2003-12-17 |
| HUP0302675A2 (hu) | 2003-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2223615T3 (es) | Procedimiento para la preparacion de atorvastatina amorfa. | |
| JP6456921B2 (ja) | エロビキシバットの結晶変態 | |
| US8796451B2 (en) | Crystalline pharmaceutical | |
| CN104284584B (zh) | 表皮生长因子受体激酶抑制剂的盐 | |
| ES2952770T3 (es) | Formas de estado sólido de apalutamida | |
| UA119181C2 (uk) | СПОЛУКИ ПІРОЛІДИНУ ЯК АНТАГОНІСТИ ІНТЕГРИНУ ανβ6 | |
| BRPI0415288B1 (pt) | COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O ÁCIDO 1-{[(a- ISOBUTANOILOXIETOXI) CARBONIL] AMINOMETIL}- 1-CICLO- HEXANO ACÉTICO CRISTALINO | |
| EA001180B1 (ru) | Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства | |
| WO2022121670A1 (zh) | Tolebrutinib的晶型及其制备方法和用途 | |
| ES2339935T3 (es) | Nuevas sales de atorvastatina y composiciones farmaceuticas que las contienen. | |
| US20240101530A1 (en) | Hdac inhibitor solid state forms | |
| ES2462502T3 (es) | Composiciones estables de SNS-595 y métodos de preparación | |
| SA06270303B1 (ar) | شكل بلوري معدل جديد من اللوبينافير | |
| US20200024299A1 (en) | Crystalline forms of a bile acid derivative | |
| JP2007516950A (ja) | プロスタグランジンｅ２アゴニストまたはアンタゴニストであるオルニチン誘導体 | |
| US20140274914A1 (en) | Ach-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof | |
| SK6182003A3 (en) | Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof | |
| ES2553574T3 (es) | Polimorfos de un principio activo farmacéutico | |
| CN110267661A (zh) | 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐 | |
| ES2309233T3 (es) | Cristales de derivado tetrapeptidico. | |
| AU2001250920A1 (en) | Crystalline pharmaceutical | |
| TW202334164A (zh) | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 | |
| JPS5817728B2 (ja) | アンピシリンナトリウムエン ノ セイホウ | |
| CN108358842A (zh) | 他喹莫德的晶型及其制备方法、其药物组合物和用途 | |
| TW200533678A (en) | A novel crystal of a triterpene derivative |